Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FOREST LABORATORIES, INC.

SummaryNewsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Forest Labs to buy Aptalis from TPG for $2.9 billion

01/08/2014 | 09:38am EDT

(Reuters) - Drugmaker Forest Laboratories Inc (>> Forest Laboratories, Inc.) said it would buy specialty pharmaceutical maker Aptalis from private equity firm TPG Capital for $2.9 billion (1.7 billion pounds) in a deal it promised would increase next year's earnings, sending its shares up nearly 14 percent.

(Reuters) - Drugmaker Forest Laboratories Inc (>> Forest Laboratories, Inc.) said it would buy specialty pharmaceutical maker Aptalis from private equity firm TPG Capital for $2.9 billion (1.7 billion pounds) in a deal it promised would increase next year's earnings, sending its shares up nearly 14 percent.

Forest, which is facing patent expirations on several of its biggest drugs, said on Wednesday that Aptalis would add 78 cents per share to fiscal 2015 earnings before special items. The deal will also boost revenue by $700 million, it added.

Analysts had been expecting a profit of $2.86 per share and revenue of $2.9 billion for the year ending March 2015, according to Thomson Reuters I/B/E/S.

Aptalis has a number of drugs to treat cystic fibrosis and gastrointestinal disorders. Forest's portfolio includes gastrointestinal and respiratory treatments.

The deal comes after activist investor Carl Icahn pressured Forest for change and threatened a proxy fight. Long-time Chief Executive Officer Howard Solomon in May said he would retire and was replaced this fall by former Bausch & Lomb CEO Brenton Saunders.

"Investors will likely see this as the new CEO executing on his 'change agent' mandate," BMO Capital Markets analyst David Maris said in a research note.

Saunders said in a statement that Aptalis would be complementary to Forest because of its gastrointestinal therapy business in the United States and Canada and cystic fibrosis products in Europe.

He expects $125 million in cost savings from combining the two companies.

Forest expects the deal, which is subject to regulatory review, to close in the first half of this year.

TPG Capital had been trying to sell Aptalis and last year held talks with Forest and other companies, including Elan Corp, which is now part of Perrigo Co (>> Perrigo Company PLC), and Sun Pharmaceutical Industries (>> Sun Pharmaceutical Industries Limited), Reuters previously reported. The talks with Forest were put on hold with the announcement of Solomon's retirement but resumed after Saunders took over.

TPG also made plans for an initial public offering of the Bridgewater, New Jersey-based company in case a deal did not materialize.

Forest was advised by Morgan Stanley (>> Morgan Stanley) and by law firms Debevoise & Plimpton LLP and Cleary Gottlieb Steen & Hamilton. Aptalis was advised by JP Morgan Securities (>> JPMorgan Chase & Co.) and law firm Ropes & Gray.

Forest shares were up 13.6 percent at $66.78 in early trading.

(Reporting by Caroline Humer in New York and Esha Dey in Bangalore; Editing by Jeffrey Benkoe and Lisa Von Ahn)


ę Reuters 2014
Stocks mentioned in the article
ChangeLast1st jan.
MORGAN STANLEY 1.87% 85.64 Delayed Quote.22.71%
SUN PHARMACEUTICAL INDUSTRIES LTD. 0.43% 671.35 Delayed Quote.12.86%
All news about FOREST LABORATORIES, INC.
2014FOREST LABORATORIESá : Actavis and Forest Receive U.S. FTC Clearance for Actavis..
BU
2014FOREST LABORATORIESá : Actavis and Forest Announce Preliminary Stockholder Merge..
BU
2014FOREST LABORATORIESá : Announces Positive Topline Results from Three Phase III T..
BU
2014FOREST LABORATORIESá : Actavis and Forest Laboratories Announce Appointment of C..
BU
2014FOREST LABORATORIESá : to Present Cariprazine Data at the International College ..
BU
2014FOREST LABORATORIESá : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA..
BU
2014FOREST LABORATORIESá : COPD Foundation Releases Groundbreaking COPE Survey Resul..
BU
2014FOREST LABORATORIESá : Announces Receipt of Requisite Consents and Expiration of..
BU
2014FOREST LABORATORIESá : Announces Intention to Continue Marketing Both NAMENDA« T..
BU
2014FOREST LABORATORIESá : Extends Expiration Time of Consent Solicitations to Elimi..
BU
More news
Sector and Competitors
1st jan.Capitalization (M$)
FOREST LABORATORIES, INC.0
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795